Concepedia

Author

Emanuela Ottaviani

University of BolognaORCID

Also Known As

Cristina Clissa, E Ottaviani, E. Ottaviani, Emanuela Ottaviani, Emanuela Ottaviani (148476)

374

Publications

4.9K

Citations

35

H-Index

61

Concepts

All Affiliations

University of BolognaIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'OrsolaIstituto Oncologico RomagnoloIstituto di Ematologia di BolognaIstituti di Ricovero e Cura a Carattere Scientifico
EO

About

Emanuela Ottaviani is an author at University of Bologna specializing in medicine, hematology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

29

1K

2

Cell Biology

13

14

386

3

Health Sciences

9

9

265

4

Engineering

2

2

65

5

Blood Transplantation

1

1

24

Emanuela Ottaviani

×

94

Publications

4.2K

Citations

34

H-Index

YearCitations

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)

Ilaria Iacobucci, Clelia Tiziana Storlazzi, Daniela Cilloni,

Blood

2009

220

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemia

Jelena Jovanović, Joannah Score, Katherine Waghorn,

Blood

2007

204

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective study

Michele Baccarani, Daniela Cilloni, Michela Rondoni,

Haematologica

2007

191

Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma

Giovanni Martinelli, Carolina Terragna, Elena Zamagni,

Journal of Clinical Oncology

2000

170

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state

Silvia Buonamici, Emanuela Ottaviani, Nicoletta Testoni,

Blood

2002

152

FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.

Giuseppe Visani, Patrizia Tosi, Pier Luigi Zinzani,

PubMed

1994

129

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation

Simona Soverini, Michèle Cavo, Claudia Cellini,

Blood

2003

120

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

Maria Chiara Fontana, Giovanni Marconi, Jelena D. Milosevic Feenstra,

Leukemia

2018

111

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

Ilaria Iacobucci, Annalisa Lonetti, Francesca Messa,

Blood

2008

109

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

Verónica Papa, Pier Luigi Tazzari, Francesca Chiarini,

Leukemia

2007

105

Page 1